ipharmacenter Consulting services

The Federal Cabinet has approved a draft legislation known as the Pharmacy Services Development Act (ApoVWG) on December 17, 2025. This new framework is designed to modernize and enhance the role of pharmacies across Germany, particularly focusing on expanding healthcare access in rural communities and streamlining administrative processes. iPharmaCenter Consulting: Find services here   Strengthening Pharmacy Infrastructure The legislation introduces financial support for par

HAS Issues Conditional Reimbursement for JAYPIRCA (Pirtobrutinib) in Relapsed or Refractory Mantle Cell Lymphoma The French Health Authority (HAS) delivered a favorable opinion for reimbursement of JAYPIRCA (pirtobrutinib) only when used as monotherapy for adult patients with relapsed or refractory mantle cell lymphoma (MCL) who have previously received a Bruton's tyrosine kinase (BTK) inhibitor and are ineligible for treatment with TECARTUS (brexucabtagene autoleucel). In ot

The European Commission has granted Marketing Authorisation to Johnson & Johnson for IMAAVY (nipocalimab), a novel FcRn-blocking antibody therapy designed to help people living with generalised myasthenia gravis (gMG). The approval covers both adult and adolescent patients aged 12 years and older who test positive for anti-acetylcholine receptor (AChR) or anti-muscle-specific kinase (MuSK) antibodies. gMG is a chronic autoimmune neuromuscular disorder that impairs communicati

Switzerland’s new understanding with the US goes beyond a minor tariff tweak and directly touches the country’s role as a pharma and med‑tech hub. Under a November memorandum of understanding, Washington will cap the country‑specific additional tariff on Swiss goods at 15%, bringing Switzerland into line with the EU and EFTA - while key pharmaceutical products remain largely exempt from the surcharge but under continued scrutiny.​   What the Switzerland–United States deal doe

May 16, 2024 Vyndaqel for Rare Heart Condition Now Available on the NHS Patients on the NHS suffering from a critical heart condition...

In their initial financial disclosures, the statutory health insurance providers reveal a surplus expenditure of approximately 1.9...

Keytruda (pembrolizumab) is suggested as an alternative for managing recurring or stubborn classical Hodgkin lymphoma in individuals aged...

January 08, 2024 ELFABRIO (pegunigalsidase alfa) - Unfavorable Reimbursement Opinion for Fabry Disease The reimbursement outlook for...

September 29, 2023 The German government commission urges stable financing for child and adolescent medicine, pediatric outpatient...

November 15, 2023 NICE not recommended Pluvicto for PSMA-positive hormone-relapsed metastatic prostate cancer Lutetium-177 vipivotide...

Find the latest healthcare and pharmaceutical news of France | HAS assessment outcomes and drug approvals in France of 2023

NHS to offer Tagrisso for lung cancer patients NHS England announced that it would roll out Tagrisso (osimertinib) for lung cancer...